216 related articles for article (PubMed ID: 25186469)
1. Are staging investigations being overused in patients with low and intermediate risk prostate cancer?
Kim L; Min M; Roos D; Nguyen L; Yeoh E
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):77-81. PubMed ID: 25186469
[TBL] [Abstract][Full Text] [Related]
2. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.
Cooperberg MR; Lubeck DP; Grossfeld GD; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):491-5. PubMed ID: 12131295
[TBL] [Abstract][Full Text] [Related]
3. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
Rutledge AB; McLeod N; Mehan N; Regan TW; Ainsworth P; Chong P; Doyle T; White M; Sanson-Fisher RW; Martin JM
BJU Int; 2018 May; 121 Suppl 3():22-27. PubMed ID: 29359883
[TBL] [Abstract][Full Text] [Related]
4. Unnecessary imaging for the staging of low-risk prostate cancer is common.
Lavery HJ; Brajtbord JS; Levinson AW; Nabizada-Pace F; Pollard ME; Samadi DB
Urology; 2011 Feb; 77(2):274-8. PubMed ID: 20932557
[TBL] [Abstract][Full Text] [Related]
5. Overuse of imaging for staging low risk prostate cancer.
Choi WW; Williams SB; Gu X; Lipsitz SR; Nguyen PL; Hu JC
J Urol; 2011 May; 185(5):1645-9. PubMed ID: 21419444
[TBL] [Abstract][Full Text] [Related]
6. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs.
Falchook AD; Salloum RG; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):243-8. PubMed ID: 24321784
[TBL] [Abstract][Full Text] [Related]
7. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria?
Cornud F; Rouanne M; Beuvon F; Eiss D; Flam T; Liberatore M; Zerbib M; Delongchamps NB
Eur J Radiol; 2012 Apr; 81(4):e591-7. PubMed ID: 21871750
[TBL] [Abstract][Full Text] [Related]
8. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
9. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
10. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
[TBL] [Abstract][Full Text] [Related]
11. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer.
Miller DC; Murtagh DS; Suh RS; Knapp PM; Schuster TG; Dunn RL; Montie JE
J Urol; 2011 Sep; 186(3):844-9. PubMed ID: 21788043
[TBL] [Abstract][Full Text] [Related]
12. MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer.
Ross I; Womble P; Ye J; Linsell S; Montie JE; Miller DC; Cher ML
J Urol; 2015 Apr; 193(4):1159-62. PubMed ID: 25444985
[TBL] [Abstract][Full Text] [Related]
13. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
14. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
Cooke EW; Shrieve DC; Tward JD
Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
[TBL] [Abstract][Full Text] [Related]
15. The viability of our specialty: the designated physician imager.
Borgstede JP
J Am Coll Radiol; 2005 Feb; 2(2):99-102. PubMed ID: 17411774
[No Abstract] [Full Text] [Related]
16. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
17. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
18. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population.
Makarov DV; Desai RA; Yu JB; Sharma R; Abraham N; Albertsen PC; Penson DF; Gross CP
J Urol; 2012 Jan; 187(1):97-102. PubMed ID: 22088337
[TBL] [Abstract][Full Text] [Related]
19. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a urological surgery quality collaborative.
Miller DC; Murtagh DS; Suh RS; Knapp PM; Dunn RL; Montie JE
J Urol; 2010 Dec; 184(6):2485-90. PubMed ID: 20961582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
